Tobaiqy M, Qashqary M, Al-Dahery S, Mujallad A, Hershan A A, Kamal M A, Helmi N
Department of Pharmacology, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
Department of Family Medicine, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
Infect Prev Pract. 2020 Sep;2(3):100061. doi: 10.1016/j.infpip.2020.100061. Epub 2020 Apr 17.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which was declared a global pandemic by the World Health Organization on 11 March 2020. The treatment guidelines for COVID-19 vary between countries, yet there is no approved treatment to date.
To report any evidence of therapeutics used for the management of patients with COVID-19 in clinical practice since emergence of the virus.
A systematic review protocol was developed based on the PRISMA statement. Articles for review were selected from Embase, Medline and Google Scholar. Readily accessible peer-reviewed, full articles in English published from 1 December 2019 to 26 March 2020 were included. The search terms included combinations of: COVID, SARS-COV-2, glucocorticoids, convalescent plasma, antiviral and antibacterial. There were no restrictions on the types of study eligible for inclusion.
Four hundred and forty-nine articles were identified in the literature search; of these, 41 studies were included in this review. These were clinical trials (=3), case reports (=7), case series (=10), and retrospective (=11) and prospective (=10) observational studies. Thirty-six studies were conducted in China (88%). Corticosteroid treatment was reported most frequently (=25), followed by lopinavir (=21) and oseltamivir (=16).
This is the first systematic review to date related to medication used to treat patients with COVID-19. Only 41 studies were eligible for inclusion, most of which were conducted in China. Corticosteroid treatment was reported most frequently in the literature.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是2019冠状病毒病（COVID-19）的病原体，世界卫生组织于2020年3月11日宣布该疾病为全球大流行。各国针对COVID-19的治疗指南各不相同，但迄今为止尚无获批的治疗方法。
报告自该病毒出现以来，临床实践中用于治疗COVID-19患者的治疗方法的相关证据。
根据PRISMA声明制定了系统评价方案。从Embase、Medline和谷歌学术中筛选用于综述的文章。纳入2019年12月1日至2020年3月26日发表的、易于获取的、经过同行评审的英文全文文章。检索词包括以下组合：COVID、SARS-COV-2、糖皮质激素、康复期血浆、抗病毒药和抗菌药。对纳入研究的类型没有限制。
文献检索共识别出449篇文章；其中，本综述纳入了41项研究。这些研究包括临床试验（=3项）、病例报告（=7项）、病例系列（=10项）以及回顾性（=11项）和前瞻性（=10项）观察性研究。36项研究在中国进行（88%）。报道最多的是皮质类固醇治疗（=25项），其次是洛匹那韦（=21项）和奥司他韦（=16项）。
这是迄今为止第一篇关于用于治疗COVID-19患者的药物的系统评价。只有41项研究符合纳入标准，其中大部分在中国进行。文献中报道最多的是皮质类固醇治疗。
